We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic Factors for Survival in Pediatric Diffuse Midline Gliomas: The Importance of T2 FLAIR Missmatch Sign and Nimotuzumab Therapy.
- Authors
Vural, Ozge; Yazol, Merve; Turkcan, Büşra Topuz; Okur, Arzu; Börcek, Alp Özgün; Pınarlı, Faruk Güçlü; Karadeniz, Ceyda
- Abstract
Purpose: The aim of this study is to investigate the clinical and radiological features, especially the importance of the T2-FLAIR mismatch sign and the response to treatment of patients diagnosed with diffuse midline gliomas (DMG) in our center. Methods: Eighteen patients treated with a diagnosis of DMG between January 2008 and January 2021 in Gazi University Medical Faculty, Department of Pediatric Oncology were retrospectively evaluated. The radiologycal evaluation was made as T2-FLAIR mismatch sign positive or negative. After a tumor board review, the diagnosis of DMG was made clinically and radiologically and all patients received local radiotherapy. Nimotuzumab was given as monotherapy or in combination with other medications Results: T2-FLAIR mismatch sign was positive for twelve patients and median OS for patients with T2-FLAIR mismatch positive and negative were 12.5 months and 9.2 months respectively (p=0.77). Median PFS for patients with T2-FLAIR mismatch sign positive and negative were 10.6 months and 4.8 months respectively (p=0.84). After nimotuzumab therapy, there was 4 cases with PR (44.4%), and 1 patient with SD (11.1%). Median OS for patients who were treated with and without nimotuzumab were 16.5 and 6.2 months respectively (p<0.05). Median PFS for patients who were treated with and without nimotuzumab were 13.3 and 3.7 months respectively (p<0.05). Conclusion: In conclusion, DMGs have poor prognosis. In our study patients with T2-FLAIR mismatch sign positive had better prognosis so it can be used as an imaging marker for prognosis. Nimotuzumab therapy may be a promising treatment option for DMG.
- Subjects
PROGNOSIS; GLIOMAS; PEDIATRIC oncology; UNIVERSITY faculty; REVIEW committees
- Publication
Gazi Medical Journal, 2023, Vol 34, Issue 4, p414
- ISSN
1300-056X
- Publication type
Article
- DOI
10.12996/gmj.2023.84